Shares of DexCom Inc. advanced 7.59% to $70.02 Friday, on what proved to be an all-around positive trading session for the ...

DexCom, Inc. DXCM reported fourth-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus ...

Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings this Thursday after market hours. Here’s what you need ...

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish ...

The Details: DexCom reported quarterly earnings of 68 cents per share, which beat the Street estimate of 65 cents, according ...

Dexcom reports 13% Q4 revenue growth to $1.26B, beating analyst expectations despite mixed analyst ratings and competitive pressures.

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

Dexcom's 2026 revenue estimates lagged analysts' expectations, according to data compiled by the London Stock Exchange Group (LSEG).

DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, Dexcom Smart Basal, for use by adults with Type 2 diabetes on glargine U-100 ...